CLAIM CARD
Despite the consistent gastrointestinal safety signal, the overall benefit-risk profile appears favorable for specific cardiovascular indications. These substantial efficacy signals in cardiometabolic endpoints suggest that the gastrointestinal risks, while statistically significant, may be clinically manageable in appropriately selected patient populations.
Evidence grade: exploratory
Contradiction status: none
Publication: 873ff54a-3a1e-4c35-b4ff-b2bb5ab68649
Provenance: Derivation Web chain
Citation Support
source_1Mohammadnia 2025source_2Li 2025source_3Ammirati 2026source_4Pascart 2026source_5Broekhoven 2022